In a 53-year-old male with ischemic heart disease presenting with acute severe dyspnea, tachypnea, tachycardia, hypoxemia (SpO₂ 88%), impaired renal function (creatinine clearance 27 mL/min) and obesity (BMI 41), suspected pulmonary embolism, which anticoagulant should be administered?

Unfractionated Heparin (UFH) via Continuous IV Infusion is the Appropriate Choice

Given this patient's severe renal impairment (CrCl 27 mL/min), hemodynamic instability (tachycardia, tachypnea, hypoxemia), and suspected high-risk pulmonary embolism, intravenous unfractionated heparin should be administered as a weight-adjusted bolus of 80 IU/kg followed by continuous infusion at 18 IU/kg/hour, with aPTT monitoring. None of the fixed-dose options listed (A, B, or C) represent the correct approach 1.

Why the Listed Options Are All Incorrect

Problems with Options A & B (Fixed-Dose UFH)

• UFH 5000 IU BID or 7500 IU q8h are prophylactic regimens, not therapeutic doses for acute PE 2
• Guidelines consistently recommend weight-adjusted dosing (80 IU/kg bolus, then 18 IU/kg/hour infusion) over fixed dosing for therapeutic anticoagulation 1, 3
• Fixed dosing leads to subtherapeutic anticoagulation and increased risk of recurrent thromboembolism

Problems with Option C (Enoxaparin 40 mg BID)

• Enoxaparin is contraindicated with CrCl <30 mL/min due to accumulation and bleeding risk 1
• The therapeutic dose for PE is 1 mg/kg BID (not 40 mg BID), which would be approximately 120-130 mg BID for this patient's weight (BMI 41 suggests ~120-130 kg)
• Even if renal function were normal, 40 mg BID is a prophylactic dose, not therapeutic 4
• LMWHs "cannot be recommended for massive PE" and require dose adjustment or avoidance in severe renal failure 1, 3

Problems with Option D (Fondaparinux)

• Fondaparinux is absolutely contraindicated with CrCl <20-30 mL/min 1
• This patient's CrCl of 27 mL/min places him at the threshold or below the safety margin
• Fondaparinux has a 15-20 hour half-life and accumulates dangerously in renal failure 1

The Correct Approach

Immediate Management

1. Start IV UFH immediately without waiting for diagnostic confirmation given high clinical probability 1, 3

   • Bolus: 80 IU/kg IV (approximately 9,600-10,400 IU for estimated weight)
   • Infusion: 18 IU/kg/hour (approximately 2,160-2,340 IU/hour)

2. Monitor aPTT at 4-6 hours after bolus, target 1.5-2.5 times control (45-75 seconds) 2, 1, 2

3. Adjust using weight-based nomogram 1, 3:

   • aPTT <35s: 80 IU/kg bolus, increase by 4 IU/kg/hour
   • aPTT 35-45s: 40 IU/kg bolus, increase by 2 IU/kg/hour
   • aPTT 46-70s: No change
   • aPTT 71-90s: Decrease by 2 IU/kg/hour
   • aPTT >90s: Stop 1 hour, decrease by 3 IU/kg/hour

Why UFH is Preferred in This Patient

Renal impairment (CrCl 27) eliminates LMWH and fondaparinux 1

Hemodynamic instability (RR 31, HR 112, SpO2 88%) suggests intermediate-to-high risk PE requiring:

• Rapid titratability of UFH
• Potential for thrombolysis consideration (UFH can be stopped immediately if needed) 1
• IV route ensures reliable absorption in a critically ill patient

Obesity (BMI 41) complicates LMWH dosing and increases bleeding risk, while UFH allows precise aPTT-guided adjustment 4

Critical Pitfalls to Avoid

• Never use prophylactic doses (5000 IU BID, 7500 IU q8h, or enoxaparin 40 mg) for acute PE treatment
• Never use LMWH or fondaparinux with CrCl <30 mL/min without extreme caution and anti-Xa monitoring
• Never use fixed-dose UFH when weight-adjusted regimens are superior 1, 3
• Monitor platelet count for heparin-induced thrombocytopenia during UFH therapy 1

Additional Considerations

This patient requires:

• Immediate oxygen therapy to correct hypoxemia 1
• Risk stratification for potential thrombolysis if hemodynamically unstable (SBP <90 mmHg) 1
• Transition to warfarin after 5 days once aPTT therapeutic and INR 2-3 for 2 consecutive days 2, 1, 2
• Consideration of IVC filter only if anticoagulation absolutely contraindicated

The answer is none of the above as written, but if forced to choose, the closest would be initiating UFH—however, it must be given as a weight-adjusted continuous IV infusion, not as fixed subcutaneous doses.